Share This:
https://ntp.niehs.nih.gov/go/14653

TDMS Study 96020-01 Pathology Tables

NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04
Route: GAVAGE                                                                                                     Time: 09:44:17

                                                            FINAL #1




       Facility:  Battelle Columbus Laboratory

       Chemical CAS #:  TEFBINARYMIX

       Lock Date:  03/27/02

       Cage Range:  All

       Reasons For Removal:    25018 Dosing Accident                   25019 Moribund Sacrifice
                               25020 Natural Death                     25021 Terminal Sacrifice

       Removal Date Range:     All

       Treatment Groups:       Include 001    0 NG /  0 UG
                               Include 004    300 NG /100 UG
                               Include 005    300 NG /300 UG
                               Include 006    300 NG /3000 UG






























a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04    
Route: GAVAGE                                                                                                     Time: 09:44:17    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       300 NG /     300 NG /     300 NG /                                  
                                                   0 UG         100 UG       300 UG       3000 UG                                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially In Study                          98           80           98           80                                     
  Early Deaths                                                                                                                      
    Moribund Sacrifice                                22           10           19           13                                     
    Natural Death                                      8           12           10           10                                     
    Dosing Accident                                    1                                      1                                     
  Survivors                                                                                                                         
    Terminal Sacrifice                                22           28           24           27                                     
                                                                                                                                    
  Animals Examined Microscopically                    53           50           53           51                                     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Esophagus                                          (53)         (50)         (53)         (50)                                   
      Perforation                                                                             1 (2%)                                
      Muscularis, Inflammation                         3 (6%)                    3 (6%)                                             
      Periesophageal Tissue, Hemorrhage                                                       1 (2%)                                
      Periesophageal Tissue, Inflammation                           1 (2%)                    1 (2%)                                
   Intestine Large, Rectum                            (53)         (50)         (53)         (51)                                   
      Parasite Metazoan                                2 (4%)       1 (2%)       1 (2%)       2 (4%)                                
      Artery, Inflammation, Chronic Active                          1 (2%)                    2 (4%)                                
   Intestine Large, Cecum                             (53)         (50)         (52)         (50)                                   
      Edema                                                                                   1 (2%)                                
      Inflammation                                                  1 (2%)                                                          
      Artery, Inflammation                                          1 (2%)                                                          
      Artery, Inflammation, Chronic Active                                                    1 (2%)                                
      Artery, Thrombosis                                            1 (2%)                                                          
      Lymphoid Tissue, Hyperplasia                                  1 (2%)                                                          
   Intestine Small, Jejunum                           (53)         (50)         (52)         (51)                                   
      Hyperplasia, Lymphoid                                                      2 (4%)                                             
      Ulcer                                                                      1 (2%)                                             
   Intestine Small, Ileum                             (53)         (50)         (52)         (50)                                   
      Hyperplasia, Lymphoid                            1 (2%)                                                                       
   Liver                                              (53)         (50)         (52)         (51)                                   
      Angiectasis                                      3 (6%)       1 (2%)       2 (4%)       3 (6%)                                
      Basophilic Focus                                 9 (17%)      4 (8%)       2 (4%)       8 (16%)                               
      Basophilic Focus, Multiple                      13 (25%)      1 (2%)       1 (2%)      10 (20%)                               
      Cholangiofibrosis                                             5 (10%)      7 (13%)     13 (25%)                               
      Clear Cell Focus                                 3 (6%)       1 (2%)       3 (6%)       5 (10%)                               
      Clear Cell Focus, Multiple                       6 (11%)      4 (8%)                    6 (12%)                               
      Eosinophilic Focus                               7 (13%)      6 (12%)      7 (13%)                                            
      Eosinophilic Focus, Multiple                     7 (13%)     21 (42%)     33 (63%)     45 (88%)                               
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    2                                                              
                                                                                                                                   
NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04    
Route: GAVAGE                                                                                                     Time: 09:44:17    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       300 NG /     300 NG /     300 NG /                                  
                                                   0 UG         100 UG       300 UG       3000 UG                                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
ALIMENTARY SYSTEM - CONT                                                                                                            
      Fatty Change, Diffuse                            3 (6%)      28 (56%)     31 (60%)     47 (92%)                               
      Fatty Change, Focal                              3 (6%)       4 (8%)       1 (2%)      11 (22%)                               
      Hematopoietic Cell Proliferation                27 (51%)     18 (36%)     19 (37%)     29 (57%)                               
      Hemorrhage                                                                              1 (2%)                                
      Hyperplasia, Nodular                                         20 (40%)     24 (46%)     21 (41%)                               
      Inflammation                                    44 (83%)     47 (94%)     48 (92%)     46 (90%)                               
      Mixed Cell Focus                                 7 (13%)                   2 (4%)       1 (2%)                                
      Mixed Cell Focus, Multiple                      19 (36%)     27 (54%)     24 (46%)     26 (51%)                               
      Necrosis                                         4 (8%)       6 (12%)      4 (8%)       7 (14%)                               
      Pigmentation                                     2 (4%)      50 (100%)    50 (96%)     44 (86%)                               
      Toxic Hepatopathy                                            44 (88%)     48 (92%)     48 (94%)                               
      Bile Duct, Cyst                                  4 (8%)       4 (8%)       5 (10%)      6 (12%)                               
      Bile Duct, Fibrosis                              1 (2%)                    4 (8%)       5 (10%)                               
      Bile Duct, Hyperplasia                           8 (15%)     20 (40%)     29 (56%)     40 (78%)                               
      Centrilobular, Degeneration                      5 (9%)       6 (12%)      4 (8%)       2 (4%)                                
      Centrilobular, Fibrosis                                       1 (2%)       1 (2%)                                             
      Hepatocyte, Hypertrophy                          1 (2%)      22 (44%)     33 (63%)     47 (92%)                               
      Hepatocyte, Multinucleated                                   42 (84%)     46 (88%)     44 (86%)                               
      Oval Cell, Hyperplasia                           2 (4%)      33 (66%)     39 (75%)     43 (84%)                               
      Portal, Fibrosis                                              3 (6%)       7 (13%)     10 (20%)                               
      Serosa, Inflammation, Chronic Active             1 (2%)                                                                       
   Mesentery                                          (47)         (31)         (47)         (47)                                   
      Artery, Inflammation, Chronic Active             1 (2%)       1 (3%)       2 (4%)       1 (2%)                                
      Fat, Necrosis                                                              1 (2%)                                             
   Oral Mucosa                                        (12)         (28)         (30)         (41)                                   
      Gingival, Hyperplasia, Squamous                  8 (67%)     21 (75%)     22 (73%)     29 (71%)                               
   Pancreas                                           (53)         (49)         (52)         (49)                                   
      Inflammation, Chronic Active                                  5 (10%)      1 (2%)       5 (10%)                               
      Necrosis                                                                                1 (2%)                                
      Acinus, Atrophy                                               4 (8%)       1 (2%)       5 (10%)                               
      Acinus, Hyperplasia                              2 (4%)                    1 (2%)       1 (2%)                                
      Acinus, Vacuolization Cytoplasmic                             3 (6%)       7 (13%)     44 (90%)                               
      Artery, Inflammation, Chronic Active                          4 (8%)       2 (4%)       3 (6%)                                
   Stomach, Forestomach                               (53)         (50)         (52)         (51)                                   
      Cyst                                                          1 (2%)                                                          
      Hyperkeratosis                                                             2 (4%)       2 (4%)                                
      Hyperplasia, Squamous                            1 (2%)       6 (12%)      7 (13%)      9 (18%)                               
      Inflammation                                                               1 (2%)       6 (12%)                               
      Mineralization                                   1 (2%)                                                                       
      Ulcer                                                         1 (2%)       2 (4%)       1 (2%)                                
      Artery, Inflammation, Chronic Active                                                    2 (4%)                                
   Stomach, Glandular                                 (53)         (50)         (52)         (51)                                   
      Ectopic Tissue                                                             1 (2%)                                             
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    3                                                              
                                                                                                                                   
NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04    
Route: GAVAGE                                                                                                     Time: 09:44:17    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       300 NG /     300 NG /     300 NG /                                  
                                                   0 UG         100 UG       300 UG       3000 UG                                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
ALIMENTARY SYSTEM - CONT                                                                                                            
      Erosion                                                       3 (6%)       1 (2%)                                             
      Mineralization                                   4 (8%)       1 (2%)       1 (2%)                                             
   Tooth                                              (23)         (25)         (35)         (42)                                   
      Peridontal Tissue, Inflammation                 23 (100%)    25 (100%)    35 (100%)    42 (100%)                              
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Blood Vessel                                       (53)         (50)         (53)         (51)                                   
      Aorta, Mineralization                                                      1 (2%)                                             
   Heart                                              (53)         (50)         (53)         (50)                                   
      Cardiomyopathy                                  22 (42%)     18 (36%)     26 (49%)     25 (50%)                               
      Inflammation, Chronic Active                     1 (2%)                                                                       
      Mineralization                                                1 (2%)                                                          
      Thrombosis                                                    1 (2%)                                                          
      Coronary Artery, Inflammation, Chronic Active                 1 (2%)                                                          
      Endocardium, Hyperplasia                                      1 (2%)                                                          
      Pericardium, Necrosis                                                      1 (2%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (53)         (49)         (52)         (51)                                   
      Angiectasis                                     17 (32%)     28 (57%)     23 (44%)      7 (14%)                               
      Atrophy                                                       2 (4%)       3 (6%)       5 (10%)                               
      Degeneration, Cystic                            13 (25%)     14 (29%)     14 (27%)     18 (35%)                               
      Hematopoietic Cell Proliferation                 1 (2%)                                                                       
      Hyperplasia                                     11 (21%)     17 (35%)     25 (48%)     21 (41%)                               
      Hypertrophy                                     47 (89%)     42 (86%)     41 (79%)     40 (78%)                               
      Necrosis                                         1 (2%)       3 (6%)                    2 (4%)                                
      Vacuolization Cytoplasmic                       11 (21%)     15 (31%)     10 (19%)     13 (25%)                               
   Adrenal Medulla                                    (52)         (49)         (52)         (49)                                   
      Hyperplasia                                     15 (29%)      8 (16%)     13 (25%)      6 (12%)                               
   Islets, Pancreatic                                 (53)         (49)         (52)         (49)                                   
      Hyperplasia                                                   1 (2%)                                                          
   Pituitary Gland                                    (53)         (50)         (52)         (51)                                   
      Angiectasis                                     17 (32%)     14 (28%)     17 (33%)      7 (14%)                               
      Cyst                                             1 (2%)                                                                       
      Cytoplasmic Alteration                                        1 (2%)                    2 (4%)                                
      Inflammation                                                               1 (2%)                                             
      Necrosis                                                                                1 (2%)                                
      Vacuolization Cytoplasmic                                                  1 (2%)       2 (4%)                                
      Pars Distalis, Hyperplasia                      13 (25%)     17 (34%)     20 (38%)     21 (41%)                               
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    4                                                              
                                                                                                                                   
NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04    
Route: GAVAGE                                                                                                     Time: 09:44:17    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       300 NG /     300 NG /     300 NG /                                  
                                                   0 UG         100 UG       300 UG       3000 UG                                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
ENDOCRINE SYSTEM - CONT                                                                                                             
   Thyroid Gland                                      (53)         (49)         (52)         (50)                                   
      Fibrosis                                                                                1 (2%)                                
      Inflammation, Chronic                                         1 (2%)                                                          
      C-Cell, Hyperplasia                             15 (28%)     16 (33%)     12 (23%)     17 (34%)                               
      Follicle, Cyst                                   2 (4%)                                                                       
      Follicular Cell, Hyperplasia                                  1 (2%)                                                          
      Follicular Cell, Hypertrophy                    14 (26%)     28 (57%)     35 (67%)     44 (88%)                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Clitoral Gland                                     (53)         (49)         (53)         (50)                                   
      Hyperplasia, Squamous                                         1 (2%)                                                          
      Inflammation                                    45 (85%)     38 (78%)     40 (75%)     40 (80%)                               
      Duct, Cyst                                      38 (72%)     41 (84%)     43 (81%)     41 (82%)                               
   Ovary                                              (53)         (48)         (52)         (50)                                   
      Atrophy                                         45 (85%)     46 (96%)     43 (83%)     36 (72%)                               
      Cyst                                            14 (26%)     16 (33%)     14 (27%)     19 (38%)                               
      Inflammation, Chronic Active                     1 (2%)                                 4 (8%)                                
      Inflammation, Granulomatous                                   1 (2%)                                                          
      Inflammation, Suppurative                                                  1 (2%)                                             
   Oviduct                                            (1)          (1)          (2)          (3)                                    
      Cyst                                             1 (100%)                  2 (100%)                                           
      Inflammation, Chronic Active                                                            3 (100%)                              
      Metaplasia, Squamous                                          1 (100%)                                                        
   Uterus                                             (53)         (50)         (52)         (50)                                   
      Adenomyosis                                                   1 (2%)                                                          
      Hemorrhage                                                    1 (2%)                                                          
      Inflammation, Chronic Active                     3 (6%)       4 (8%)       7 (13%)      8 (16%)                               
      Inflammation, Suppurative                        3 (6%)       2 (4%)      10 (19%)      8 (16%)                               
      Metaplasia, Squamous                            27 (51%)     27 (54%)     36 (69%)     34 (68%)                               
      Cervix, Cyst                                                  1 (2%)                                                          
      Endometrium, Hyperplasia, Cystic                28 (53%)     25 (50%)     18 (35%)     15 (30%)                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Bone Marrow                                        (53)         (50)         (53)         (51)                                   
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    5                                                              
                                                                                                                                   
NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04    
Route: GAVAGE                                                                                                     Time: 09:44:17    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       300 NG /     300 NG /     300 NG /                                  
                                                   0 UG         100 UG       300 UG       3000 UG                                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
HEMATOPOIETIC SYSTEM - CONT                                                                                                         
      Hyperplasia                                     39 (74%)     38 (76%)     48 (91%)     39 (76%)                               
   Lymph Node                                         (4)          (2)          (7)          (5)                                    
      Angiectasis                                                                1 (14%)                                            
      Inguinal, Hyperplasia, Plasma Cell                                         1 (14%)                                            
      Lumbar, Ectasia                                  4 (100%)                  1 (14%)      1 (20%)                               
      Lumbar, Hemorrhage                                                                      1 (20%)                               
      Lumbar, Hyperplasia, Plasma Cell                 4 (100%)                                                                     
      Mediastinal, Ectasia                                                                    2 (40%)                               
      Mediastinal, Hemorrhage                                                    1 (14%)      2 (40%)                               
      Mediastinal, Hyperplasia, Histiocytic                                      1 (14%)      1 (20%)                               
      Mediastinal, Hyperplasia, Lymphoid                            1 (50%)                                                         
      Mediastinal, Hyperplasia, Plasma Cell                         1 (50%)                   1 (20%)                               
      Pancreatic, Hyperplasia, Histiocytic                                       1 (14%)                                            
      Pancreatic, Pigmentation                                                   1 (14%)                                            
      Renal, Ectasia                                                             1 (14%)                                            
      Renal, Hyperplasia, Histiocytic                                            1 (14%)                                            
      Renal, Hyperplasia, Plasma Cell                                            1 (14%)                                            
   Lymph Node, Mandibular                             (53)         (49)         (50)         (49)                                   
      Congestion                                                                 1 (2%)                                             
      Ectasia                                                                    3 (6%)       2 (4%)                                
      Hyperplasia, Lymphoid                            1 (2%)                    2 (4%)       2 (4%)                                
      Hyperplasia, Plasma Cell                        37 (70%)     33 (67%)     36 (72%)     32 (65%)                               
   Lymph Node, Mesenteric                             (53)         (49)         (52)         (49)                                   
      Hemorrhage                                                                 1 (2%)                                             
      Hyperplasia, Histiocytic                                                   1 (2%)                                             
      Hyperplasia, Lymphoid                                         1 (2%)                                                          
      Hyperplasia, Plasma Cell                                      1 (2%)                    2 (4%)                                
   Spleen                                             (53)         (49)         (52)         (49)                                   
      Fibrosis                                                                   1 (2%)                                             
      Hematopoietic Cell Proliferation                51 (96%)     41 (84%)     47 (90%)     45 (92%)                               
      Pigmentation                                    47 (89%)     48 (98%)     51 (98%)     49 (100%)                              
      Lymphoid Follicle, Atrophy                                    5 (10%)      4 (8%)       2 (4%)                                
      Red Pulp, Atrophy                                1 (2%)       1 (2%)                    1 (2%)                                
   Thymus                                             (53)         (48)         (50)         (47)                                   
      Atrophy                                         33 (62%)     48 (100%)    42 (84%)     45 (96%)                               
      Cyst                                                                       1 (2%)                                             
      Hemorrhage                                       1 (2%)                    3 (6%)                                             
      Hyperplasia, Lymphoid                            2 (4%)                                                                       
      Epithelial Cell, Hyperplasia                                               1 (2%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    6                                                              
                                                                                                                                   
NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04    
Route: GAVAGE                                                                                                     Time: 09:44:17    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       300 NG /     300 NG /     300 NG /                                  
                                                   0 UG         100 UG       300 UG       3000 UG                                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
INTEGUMENTARY SYSTEM - CONT                                                                                                         
   Mammary Gland                                      (53)         (50)         (53)         (51)                                   
      Cyst                                             3 (6%)       2 (4%)       3 (6%)       2 (4%)                                
      Hyperplasia                                     29 (55%)     14 (28%)     22 (42%)     15 (29%)                               
      Inflammation, Granulomatous                      5 (9%)       2 (4%)       3 (6%)                                             
      Duct, Cyst                                       1 (2%)                                                                       
   Skin                                               (53)         (50)         (53)         (51)                                   
      Angiectasis                                      1 (2%)                                                                       
      Cyst Epithelial Inclusion                                                  1 (2%)                                             
      Edema                                                                                   1 (2%)                                
      Fibrosis                                         1 (2%)                                                                       
      Inflammation                                                                            2 (4%)                                
      Necrosis                                                                                1 (2%)                                
      Subcutaneous Tissue, Edema                                                              1 (2%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   Skeletal Muscle                                    (1)          (1)          (1)          (3)                                    
      Inflammation                                                                            1 (33%)                               
      Necrosis                                                                                1 (33%)                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   Brain                                              (53)         (50)         (52)         (51)                                   
      Hemorrhage                                                    1 (2%)       1 (2%)                                             
      Hydrocephalus                                    1 (2%)       1 (2%)                    1 (2%)                                
      Cerebellum, Hemorrhage                                        1 (2%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (53)         (50)         (53)         (50)                                   
      Hemorrhage                                                    1 (2%)                                                          
      Infiltration Cellular, Histiocyte               47 (89%)     49 (98%)     46 (87%)     40 (80%)                               
      Inflammation                                     8 (15%)      2 (4%)       4 (8%)       2 (4%)                                
      Metaplasia, Squamous                                          3 (6%)       2 (4%)       6 (12%)                               
      Mineralization                                                             1 (2%)                                             
      Alveolar Epithelium, Hyperplasia                23 (43%)      5 (10%)      5 (9%)       8 (16%)                               
      Alveolar Epithelium, Metaplasia, Bronchiolar                 39 (78%)     34 (64%)     30 (60%)                               
      Mediastinum, Necrosis                                         1 (2%)       1 (2%)                                             
      Serosa, Inflammation                                                       1 (2%)                                             
   Nose                                               (53)         (50)         (53)         (51)                                   
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    7                                                              
                                                                                                                                   
NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04    
Route: GAVAGE                                                                                                     Time: 09:44:17    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       300 NG /     300 NG /     300 NG /                                  
                                                   0 UG         100 UG       300 UG       3000 UG                                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
RESPIRATORY SYSTEM - CONT                                                                                                           
      Hyperplasia                                                                             1 (2%)                                
      Inflammation                                    22 (42%)     17 (34%)     13 (25%)     15 (29%)                               
      Nerve, Degeneration                                                                     1 (2%)                                
      Olfactory Epithelium, Degeneration               1 (2%)       1 (2%)                                                          
      Olfactory Epithelium, Dysplasia                                                         1 (2%)                                
      Olfactory Epithelium, Metaplasia                 4 (8%)       5 (10%)      6 (11%)      5 (10%)                               
      Respiratory Epithelium, Hyperplasia             10 (19%)     14 (28%)     11 (21%)     12 (24%)                               
      Respiratory Epithelium, Metaplasia               1 (2%)                                                                       
   Trachea                                            (53)         (50)         (53)         (50)                                   
      Inflammation                                     1 (2%)                                                                       
      Peritracheal Tissue, Inflammation                                                       1 (2%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   Eye                                                (53)         (50)         (52)         (51)                                   
      Anterior Chamber, Ciliary Body, Cornea,                                                                                       
        Inflammation                                                2 (4%)       1 (2%)                                             
      Cornea, Inflammation                                          1 (2%)       1 (2%)                                             
      Retina, Atrophy                                  1 (2%)                    2 (4%)       5 (10%)                               
   Harderian Gland                                    (53)         (49)         (52)         (51)                                   
      Inflammation                                    20 (38%)     15 (31%)     14 (27%)     17 (33%)                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (53)         (48)         (52)         (51)                                   
      Accumulation, Hyaline Droplet                    2 (4%)                    1 (2%)       2 (4%)                                
      Calculus Micro Observation Only                  7 (13%)      6 (13%)      4 (8%)       6 (12%)                               
      Casts Protein                                    2 (4%)                                                                       
      Cyst                                                          1 (2%)       1 (2%)                                             
      Hydronephrosis                                                                          2 (4%)                                
      Infarct                                                                                 2 (4%)                                
      Inflammation, Chronic Active                     1 (2%)                    1 (2%)       1 (2%)                                
      Inflammation, Suppurative                        5 (9%)       6 (13%)      5 (10%)      3 (6%)                                
      Mineralization                                  42 (79%)     39 (81%)     42 (81%)     33 (65%)                               
      Nephropathy                                     29 (55%)     30 (63%)     34 (65%)     34 (67%)                               
      Pigmentation                                                  2 (4%)       7 (13%)     17 (33%)                               
      Pelvis, Dilatation                               1 (2%)       4 (8%)       2 (4%)                                             
      Pelvis, Inflammation                             3 (6%)       1 (2%)       3 (6%)       8 (16%)                               
      Renal Tubule, Degeneration                                                 2 (4%)                                             
      Renal Tubule, Hyperplasia                                                               1 (2%)                                
      Transitional Epithelium, Hyperplasia             2 (4%)       6 (13%)     11 (21%)      9 (18%)                               
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    8                                                              
                                                                                                                                   
NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04    
Route: GAVAGE                                                                                                     Time: 09:44:17    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       300 NG /     300 NG /     300 NG /                                  
                                                   0 UG         100 UG       300 UG       3000 UG                                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
URINARY SYSTEM - CONT                                                                                                               
   Ureter                                             (1)                       (1)          (1)                                    
      Inflammation                                     1 (100%)                  1 (100%)     1 (100%)                              
      Transitional Epithelium, Hyperplasia             1 (100%)                               1 (100%)                              
   Urinary Bladder                                    (53)         (49)         (52)         (50)                                   
      Inflammation                                     7 (13%)      3 (6%)       7 (13%)      8 (16%)                               
      Transitional Epithelium, Hyperplasia                                       1 (2%)       1 (2%)                                
                                                                                                                                    
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page    9                                                              
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------